X

Given the current situation, we understand that people may experience worry and even fear about how their disease and treatment may impact their personal risk. Sanofi Genzyme is committed to patient safety and to transparent communication. We are taking COVID-19 seriously, and we are committed to updating the communities we serve with relevant information related to our medicines to help inform health decisions.

As COVID-19 has emerged only recently, there are no available data regarding the impact of the virus on our current therapies. At this time, if you have general questions about our therapies, you should consult the current U.S. Prescribing Information (USPI).

Each patient’s situation is unique, and patients and their healthcare providers are in the best position to make decisions regarding their care. In addition to local public health authority guidance, and local guidance from medical or patient associations, more information about COVID-19 can be found on the Centers for Disease Control’s (CDC) website or the World Health Organization’s (WHO) website.

MAT-US-2001111

LEMTRADA is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Since treatment with LEMTRADA can increase your risk of getting certain conditions and diseases, LEMTRADA is generally prescribed for people who have tried 2 or more MS medicines that have not worked well enough. LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS). It is not known if LEMTRADA is safe and effective for use in children under 17 years of age.

LEMTRADA is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Since treatment with LEMTRADA can increase your risk of getting certain conditions and diseases, LEMTRADA is generally prescribed for people who have tried 2 or more MS medicines that have not worked well enough. LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS). It is not known if LEMTRADA is safe and effective for use in children under 17 years of age.

Information about financial support to help with the cost of LEMTRADA treatment

FINANCIAL SUPPORT

If you need help paying for LEMTRADA, you may be eligible for financial support, including the LEMTRADA Co-Pay program.

LEARN MORE


Personal support from MS One to One

PERSONAL SUPPORT

LEMTRADA offers support that is with you every step of the way. Explore some of the help you can access—from dedicated nurses to information and resources.

FIND SUPPORT


Tips to support someone living with relapsing MS

SUPPORT PARTNER TIPS

People with relapsing MS may need the support of family and friends. Find tips for being a support partner.

SEE TIPS


Find helpful resources to learn about LEMTRADA and relapsing multiple sclerosis

HELPFUL RESOURCES

Get information and materials to help you learn about LEMTRADA and have a conversation with your healthcare provider.

GET RESOURCES


Find a healthcare provider or facility that is certified by the LEMTRADA REMS

HCP LOCATOR TOOLS

Search for healthcare providers and facilities that are certified by the LEMTRADA REMS.

USE LOCATOR TOOL


Charles
LEMTRADA
PATIENT

I am not just
a patient.

I’m a
partner.

Charles refused to settle when treatment wasn’t working well enough.

Nurse Lynn
MS One to one

We can
help you

Along your
MS journey.

Having the right support makes a real difference.

Real LEMTRADA patients sharing real stories

REAL PATIENTS SHARING
REAL STORIES

Meet real relapsing MS patients taking an active role in treatment.

Important Safety Information See More

LEMTRADA can cause serious side effects including serious autoimmune problems. Some people receiving LEMTRADA develop a condition where the immune cells in your body attack other cells or organs in the body (autoimmunity), which can be serious and may cause death. Serious autoimmune problems may include: